CALC · Calcimedica, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - |
| R&D | $3.48M | - | $3.85M | $4.05M | $4.22M | - | $3.55M | $4.16M | $2.94M | - |
| SG&A | $2.13M | - | $1.77M | $2.57M | $2.27M | - | $2.19M | $2.37M | $2.82M | - |
| Total Operating Expenses | $5.61M | - | $5.62M | $6.62M | $6.50M | - | $5.74M | $6.53M | $5.77M | - |
| D&A | $7.0K | - | - | - | $15.0K | - | $15.0K | $15.0K | $15.0K | - |
| Operating Income | ($5.61M) | - | ($5.62M) | ($6.62M) | ($6.50M) | - | ($5.74M) | ($6.53M) | ($5.77M) | - |
| Interest Expense | $319.0K | - | $0 | $324.0K | $0 | - | - | - | - | - |
| Income Tax | $0 | - | $0 | $0 | $0 | - | $0 | $0 | $0 | - |
| Net Income | $4.98M | - | ($7.80M) | ($5.96M) | ($5.04M) | - | ($5.62M) | ($3.95M) | $130.0K | - |
| EPS - Basic | $0.31 | - | ($0.52) | ($0.40) | ($0.36) | - | ($0.50) | ($0.36) | $0.01 | - |
| EPS - Diluted | $0.30 | - | ($0.52) | ($0.40) | ($0.36) | - | ($0.50) | ($0.36) | $0.01 | - |
Balance Sheet
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $8.16M | $11.52M | $5.47M | $5.92M | $12.56M | $7.93M | $9.15M | $5.06M | $6.75M | $5.53M |
| Accounts Receivable | - | - | - | - | - | - | - | - | - | - |
| Inventory | - | - | - | - | - | - | - | - | - | - |
| Accounts Payable | $1.68M | $1.16M | $1.13M | $1.91M | $2.02M | $2.00M | $1.54M | $2.14M | $1.53M | $1.42M |
| Current Assets | $8.55M | $13.53M | $14.85M | $18.96M | $25.22M | $19.66M | $15.69M | $20.44M | $26.60M | $11.61M |
| Total Assets | $8.61M | $13.59M | $14.91M | $19.08M | $25.35M | $19.79M | $16.21M | $21.05M | $27.13M | $12.19M |
| Current Liabilities | $5.31M | $3.78M | $3.68M | $3.48M | $4.46M | $3.68M | $3.78M | $3.91M | $4.29M | $4.03M |
| Long-term Debt | - | - | - | - | - | - | - | - | - | - |
| Total Liabilities | $9.71M | $20.23M | $15.18M | $12.98M | $14.46M | $5.38M | $7.18M | $7.21M | $9.89M | $4.03M |
| Stockholders' Equity | ($1.10M) | ($6.64M) | ($268.0K) | $6.10M | $10.89M | $14.41M | $9.03M | $13.84M | $17.25M | $8.16M |
| Retained Earnings | ($184.35M) | ($189.33M) | ($178.57M) | ($170.76M) | ($164.81M) | ($159.76M) | ($155.51M) | ($149.89M) | ($145.93M) | ($146.06M) |
Cash Flow
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | ($4.86M) | - | - | - | ($4.88M) | - | - | - | ($4.71M) | - |
| Investing Cash Flow | $1.50M | - | - | - | ($1.24M) | - | - | - | ($13.10M) | - |
| Financing Cash Flow | $0 | - | - | - | $10.74M | - | - | - | $19.04M | - |
| CapEx | $0 | - | - | - | $0 | - | - | - | - | - |
| Free Cash Flow | ($4.86M) | - | - | - | ($4.88M) | - | - | - | - | - |
Ratios
| Metric | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | - | - | - | - | - | - | - | - | - | - |
| Operating margin | - | - | - | - | - | - | - | - | - | - |
| EBITDA margin | - | - | - | - | - | - | - | - | - | - |
| Net margin | - | - | - | - | - | - | - | - | - | - |
| Free cash flow margin | - | - | - | - | - | - | - | - | - | - |
| FCF / Net income | -0.98 | - | - | - | 0.97 | - | - | - | - | - |
| R&D / Revenue | - | - | - | - | - | - | - | - | - | - |
| SG&A / Revenue | - | - | - | - | - | - | - | - | - | - |
| Effective tax rate | 0.0% | - | - | - | - | - | - | - | 0.0% | - |
| Return on assets | 57.8% | - | -52.3% | -31.2% | -19.9% | - | -34.7% | -18.8% | 0.5% | - |
| Return on equity | -450.7% | - | 2911.9% | -97.6% | -46.3% | - | -62.2% | -28.6% | 0.8% | - |
| Return on invested capital | - | - | - | - | - | - | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | 1.61 | 3.58 | 4.04 | 5.45 | 5.66 | 5.34 | 4.15 | 5.22 | 6.21 | 2.88 |
| Quick ratio | 1.61 | 3.58 | 4.04 | 5.45 | 5.66 | 5.34 | 4.15 | 5.22 | 6.21 | 2.88 |
| Cash ratio | 1.54 | 3.05 | 1.49 | 1.70 | 2.82 | 2.15 | 2.42 | 1.29 | 1.58 | 1.37 |
| Leverage | ||||||||||
| Debt / Equity | - | - | - | - | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | -17.6x | - | - | -20.4x | - | - | - | - | - | - |
| Equity multiplier | -7.80 | -2.05 | -55.65 | 3.13 | 2.33 | 1.37 | 1.80 | 1.52 | 1.57 | 1.49 |
| Liabilities / Assets | 1.13 | 1.49 | 1.02 | 0.68 | 0.57 | 0.27 | 0.44 | 0.34 | 0.36 | 0.33 |
| Efficiency | ||||||||||
| Asset turnover | - | - | - | - | - | - | - | - | - | - |
| Inventory turnover | - | - | - | - | - | - | - | - | - | - |
| Days sales outstanding | - | - | - | - | - | - | - | - | - | - |
| Days inventory outstanding | - | - | - | - | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - | - | - | - | - |
| Valuation | ||||||||||
| P / E | 1.8x | - | - | - | - | - | - | - | 416.0x | - |
| P / B | - | - | - | 3.9x | 2.5x | - | 5.5x | 3.2x | 2.4x | - |
| P / S | - | - | - | - | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Operating income growth (YoY) | 13.6% | - | 2.1% | -1.4% | -12.7% | - | -18.7% | 0.8% | 74.2% | - |
| Net income growth (YoY) | - | - | -38.9% | -50.6% | - | - | -21.6% | 37.3% | - | - |
| EPS growth (YoY) | - | - | -4.0% | -11.1% | - | - | 39.0% | 67.6% | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | 0.5% | - | - | - | - | - | - | - | - | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | - | - | - | -55.9% | -36.9% | 76.7% | -25.7% | -14.7% | -21.7% | -77.3% |
Peer comparison
Same SIC group: Pharmaceutical Preparations
Comparing CalciMedica against the 5 most active filers in the same SIC group.